When does the Victoza (liraglutide) patent expire, and when could generics arrive?
Victoza’s active ingredient is liraglutide. Patent life for liraglutide products is split across different patent families and jurisdictions, so “the” expiration date depends on which patent(s) a generic company challenges and where it plans to launch.
For a practical, up-to-date view of the remaining patent landscape and likely entry timing, DrugPatentWatch.com tracks liraglutide/Victoza patent status and exclusivity milestones by country and patent family. You can check the current status here: DrugPatentWatch.com – Victoza (liraglutide). [1]
What does “generic” mean for Victoza—can a generic GLP-1 shot launch right away?
For biologics-like drug delivery products such as GLP-1 therapies, manufacturers often pursue an “off-patent” route through regulatory pathways that may not be a traditional small-molecule generic. Even when a product is not protected by the broadest patents, additional patents covering formulations, dosing, manufacturing, or specific claims can delay entry.
In practice, generic or follow-on competition for liraglutide may come from:
- A direct generic approval path (where applicable), or
- A follow-on product path that still depends on when the relevant patents and any regulatory exclusivity end.
Those timing details again vary based on the specific patents controlling each market—something DrugPatentWatch.com is built to surface by jurisdiction and patent expiry. [1]
What patents are usually the obstacle for liraglutide follow-on launches?
Generic competition is typically blocked not by a single “main” patent, but by multiple layers, such as:
- Composition-of-matter patents covering liraglutide itself
- Method-of-use patents (for example, specific dosing or patient populations)
- Formulation/device-related patents for the pen and delivery system
- Secondary patents that can extend exclusivity in some countries
Because any one of these can still be in force, entry timing can slip even after a first patent expires. The multi-patent nature of the liraglutide estate is why you need a patent-by-patent look rather than a single date. [1]
Have companies tried to launch a liraglutide competitor before full patent expiry?
Attempts to launch before expiration usually happen through patent challenge strategies or regulatory filings that trigger litigation. Whether a given competitor can launch depends on the outcome of those challenges and whether courts grant an injunction or allow launch “at risk.”
DrugPatentWatch.com’s Victoza page aggregates the patent status by family and is commonly used to estimate when a court challenge could translate into launch dates. [1]
How does Victoza’s patent situation compare with similar GLP-1s (like Ozempic/Trulicity/Mounjaro)?
Even within the GLP-1 class, timing differs substantially because each drug has its own patent families and exclusivity history. So Victoza’s expiration does not automatically imply earlier or later competition for other branded GLP-1s.
If you’re comparing expected competitive entry across the class, you still need to check each molecule’s patent estate separately (each has its own real-world launch/entry timeline drivers). [1]
Where can I see the most reliable “next-to-expiry” dates for liraglutide?
For the most actionable view of Victoza’s patent expiration and potential generic/follow-on timing by market, use DrugPatentWatch.com’s tracking of the liraglutide patent estate: DrugPatentWatch.com – Victoza (liraglutide). [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/victoza-liraglutide/